成都华神科技集团股份有限公司 2024 年年度报告商誉减值 成都华神科技集团股份有限公司 2024 年度商誉减值测试报告 一、是否进行减值测试 是 □否 二、是否在减值测试中取得以财务报告为目的的评估报告 是 □否 | 资产组名称 | 评估机构 | 评估师 | 评估报告编号 | 评估价值类型 | 评估结果 | | --- | --- | --- | --- | --- | --- | | 四川蓝光矿泉水 | 沃克森（北京）国际 | 成本云、伍智红 | 沃克森国际评报字 | 资产组可收回金 | 不减值 | | 有限公司资产组 | 资产评估有限公司 | | （2025）第 0657 号 | 额 | | | 四川蓝光物流有 | 沃克森（北京）国际 | 成本云、伍智红 | 沃克森评报字 | 资产组可收回金 | 不减值 | | 限公司资产组 | 资产评估有限公司 | | （2025）第 0637 号 | 额 | | | 成都远泓矿泉水 | 沃克森（北京）国际 | 成本云、伍智红 | 沃克森评报字 | 资产组可收回金 | 不减值 | | 有限公司资产组 | 资产评估有限公司 | | （2025）第 0766 号 | 额 ...

成都华神科技集团股份有限公司 董事会审计委员会对会计师事务所2024年度履职情况评估 及履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治 理准则》《国有企业、上市公司选聘会计师事务所管理办法》《深圳证券交易 所上市公司自律监管指引第1号——主板上市公司规范运作》和《公司章程》等 有关规定，成都华神科技集团股份有限公司（以下简称"公司"）董事会审计委 员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计委员会对会 计师事务所2024年度履行监督职责的情况汇报如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 四川华信（集团）会计师事务所（特殊普通合伙）（以下简称"四川华 信"），初始成立于1988年6月，2013年11月27日改制为特殊普通合伙企业，注 册地址为泸州市江阳中路28号楼三单元2号，总部办公地址：成都市武侯区洗面 桥街18号金茂礼都南28楼。首席合伙人为李武林。四川华信自1997年开始一直 从事证券服务业务，截至2024年12月31日，四川华信共有合伙人51人、注册会 计师134人、签署过证券服务业务审计报告的注册会计师人数102 ...

成都华神科技集团股份有限公司 2024 年年度财务报告 成都华神科技集团股份有限公司 2024 年年度财务报告 2025 年 04 月 1 成都华神科技集团股份有限公司 2024 年年度财务报告 财务报告 一、审计报告 | 审计意见类型 | 标准的无保留意见 | | --- | --- | | 审计报告签署日期 | 2025 年 04 月 27 日 | | 审计机构名称 | 四川华信（集团）会计师事务所（特殊普通合伙） | | 审计报告文号 | 川华信审（2025）第 0055 号 | | 注册会计师姓名 | 何寿福、凡波、王慧 | 审计报告正文 审计报告 川华信审（2025）第 0055 号 成都华神科技集团股份有限公司全体股东： 一、审计意见 我们审计了成都华神科技集团股份有限公司（以下简称"贵公司"）财务报表，包括 2024 年 12 月 31 日的合并及 母公司资产负债表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益变动表以及相 关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了贵公司 2024 年 12 月 31 日 的 ...

成都华神科技集团股份有限公司 2024 年度财务决算报告 公司 2024 年度财务报表按照企业会计准则的规定编制，在所有重大方面公 允反映了合并及母公司 2024 年 12 月 31 日的财务状况、2024 年度的经营成果和 现金流量。报告已经四川华信（集团）会计师事务所（特殊普通合伙）审计，并 由该所出具了川华信审（2025）第 0055 号标准无保留意见的审计报告。 二、2024 年公司主要财务数据 （一）经营成果 | 单位：万元 | | --- | | 项目 | 2024 年 | 2023 年 | 本年比上年 | | --- | --- | --- | --- | | | | | 增减 | | 营业收入 | 86,397.66 | 100,337.66 | -13.89% | | 营业成本 | 42,823.81 | 60,717.05 | -29.47% | | 税金及附加 | 1,450.07 | 1,186.40 | 22.22% | | 期间费用 | 41,963.73 | 35,063.40 | 19.68% | | 其中：销售费用 | 28,167.26 | 21,498.52 | 31.0 ...

证券代码：000790 证券简称：华神科技 公告编号：2025-008 成都华神科技集团股份有限公司 关于召开 2024 年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 经成都华神科技集团股份有限公司（以下简称"公司"）第十三届董事会第二十次会 议审议决定，公司将以现场表决与网络投票相结合的方式召开2024年年度股东大会。现 将有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次 （1）现场会议时间 2025年5月22日（星期四）下午14:00。 （2）网络投票时间 2025年5月22日，其中，通过深圳证券交易所交易系统进行网络投票的时间为：2025 年5月22日9:15--9:25，9:30--11:30，13:00--15:00；通过深圳证券交易所互联网投票系统 投票的时间为：2025年5月22日9:15至15:00期间的任意时间。 5、会议召开及投票表决方式 本次股东大会采用现场表决与网络投票相结合的方式召开。 成都华神科技集团股份有限公司2024年年度股东大会 2、股东大会的召集人 董事会 3、会议召开的合法、合规性 本次 ...

证券代码：000790 证券简称：华神科技 公告编号：2025-005 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都华神科技集团股份有限公司（以下简称"公司"）第十三届监事会第十 四次会议于2025年4月27日以现场会议的方式在公司会议室召开。本次会议通知 于2025年4月17日发出，应到监事3人，实到监事3人，会议由公司监事会主席苏 蓉蓉女士主持，本次会议的召开符合有关法律、行政法规、部门规章、规范性 文件和公司章程的规定。 二、监事会会议审议情况 （一）审议通过《2024 年年度报告及其摘要》 经核查，监事会认为：公司《2024 年年度报告》全文及其摘要的编制和审 议程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整 地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网披露的相关公告文件。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 成都华神科技集团股份有限公司 第十三届监事会第十四次会议决议公告 本议案尚需提交 2024 年年度股东大会审议。 （二 ...

证券代码：000790 证券简称：华神科技 公告编号：2025-004 成都华神科技集团股份有限公司 第十三届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都华神科技集团股份有限公司（以下简称"公司"）第十三届董事会第二 十次会议于2025年4月27日以现场与通讯表决相结合的方式在公司会议室召开。 本次会议通知于2025年4月17日发出，本次会议应出席董事9人，实际出席董事9 人。会议由公司董事长黄明良先生主持，公司全体监事、高级管理人员列席了 会议。本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的有关规定。 二、董事会会议审议情况 （一）审议通过《2024 年年度报告及其摘要》 董事会审议认为公司《2024 年年度报告》及《2024 年年度报告摘要》内容 真实、准确、完整，不存在任何虚假记载、误导性陈述或重大遗漏。本议案已 经公司董事会审计委员会审议通过。具体内容详见公司同日在巨潮资讯网披露 的相关公告文件。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案 ...

证券代码：000790 证券简称：华神科技 公告编号：2025-006 | 项目 | 本年度 | 上年度 | 上上年度 | | --- | --- | --- | --- | | 现金分红总额（元） | 0 | 6,237,193.64 | 6,281,425.64 | | 回购注销总额（元） | 0 | 0 | 0 | | 归属于上市公司股东的净利润（元） | -6,690,166.26 | 27,659,463.93 | 41,217,518.38 | | 合并报表本年度末累计未分配利润（元） | | 215,897,052.82 | | | 母公司报表本年度末累计未分配利润（元） | | 235,768,607.78 | | | 上市是否满三个完整会计年度 | | 是 | | | 最近三个会计年度累计现金分红总额（元） | | 12,518,619.28 | | | 最近三个会计年度累计回购注销总额（元） | | 0 | | | 最近三个会计年度平均净利润（元） | | 20,728,938.68 | | | 最近三个会计年度累计现金分红及回购注销总 | | 12,518,619.28 | | | 额（ ...

Financial Performance - The company's operating revenue for 2024 was ¥863,976,571.55, a decrease of 13.89% compared to ¥1,003,376,637.04 in 2023[22] - The net profit attributable to shareholders for 2024 was -¥6,690,166.26, representing a decline of 124.19% from ¥27,659,463.93 in the previous year[22] - The net profit after deducting non-recurring gains and losses was -¥15,563,890.23, down 143.94% from ¥35,421,382.66 in 2023[22] - The basic earnings per share for 2024 was -¥0.01, a decrease of 125.00% from ¥0.04 in 2023[22] - The weighted average return on net assets was -0.65%, down from 2.72% in the previous year[22] - The company reported a significant decline in both net profit and revenue, indicating potential challenges in its operational performance[22] - In Q1 2024, the company reported revenue of approximately ¥179.28 million, which increased to ¥278.56 million in Q2, but decreased to ¥205.24 million in Q3 and ¥200.90 million in Q4[26] - The net profit attributable to shareholders was ¥2.28 million in Q1, rising to ¥6.83 million in Q2, but turned negative with a loss of ¥3.37 million in Q3 and ¥12.43 million in Q4[26] - The total revenue for 2024 was approximately ¥863.98 million, representing a decrease of 13.89% compared to ¥1,003.38 million in 2023[61] Cash Flow and Assets - The net cash flow from operating activities increased by 35.57% to ¥64,278,831.37, compared to ¥47,414,104.46 in 2023[22] - Total assets at the end of 2024 reached ¥2,249,238,967.54, an increase of 5.43% from ¥2,133,478,855.05 at the end of 2023[22] - The net assets attributable to shareholders decreased by 0.71% to ¥1,025,895,578.65 from ¥1,033,194,655.74 in 2023[22] - The total cash inflow from financing activities increased by 38.94% to ¥680,067,649.83 in 2024, up from ¥489,464,280.26 in 2023[76] - The company's total assets included cash and cash equivalents of ¥209,467,279.68, accounting for 9.31% of total assets at the end of 2024[78] Government Support and Non-Recurring Gains - The company received government subsidies amounting to ¥5.63 million in 2024, up from ¥3.98 million in 2023, indicating a positive trend in government support[27] - The total non-recurring gains and losses for 2024 amounted to approximately ¥8.87 million, a significant recovery from a loss of ¥7.76 million in 2023[27] Market and Product Development - The pharmaceutical manufacturing industry in China is projected to maintain a revenue of ¥2.53 trillion in 2024, with a slight profit decline of 1.1%[30] - The company anticipates further market expansion and product innovation in response to the evolving healthcare landscape and consumer demands[30] - The health beverage market is expected to grow from ¥190 billion in 2019 to ¥310 billion by 2025, driven by health trends and innovative products[34] - The company has established a three-tier collaborative marketing network covering various regions in China, focusing on cardiovascular, ENT, and pediatric respiratory diseases, enhancing its competitive edge in these specialized treatment areas[35] - The core product, Sanqi Tongshu Capsule, was selected for the National Traditional Chinese Medicine Procurement Alliance in 2024 and is recommended in the "Guidelines for the Prevention and Treatment of Stroke with Integrated Traditional Chinese and Western Medicine (2023 Edition)"[35] Research and Development - The company has applied for and acquired a total of 203 patents, with 168 authorized patents, including 4 international invention patents[47] - The company is advancing the development of a new product, Sanqi Tongshu Capsule, aimed at enhancing clinical value and market presence[73] - The number of R&D personnel increased to 166 in 2024, representing a growth of 23.88% compared to 134 in 2023[75] - R&D investment amounted to ¥28,178,452.75 in 2024, a decrease of 11.67% from ¥31,902,380.11 in 2023[75] Operational Efficiency and Management - The organization implemented a flat management structure to enhance operational efficiency, focusing on customer needs and market-driven strategies[59] - The company plans to strategically divest its steel structure business to concentrate resources on the core pharmaceutical industry[57] - The company has established a financial management center with a strict accounting system, ensuring independent financial decision-making without interference from shareholders[122] - The company has a complete internal management structure that operates independently from controlling shareholders[121] Environmental Management - The company has implemented strict environmental management practices, including obtaining necessary pollution discharge permits[169] - The pharmaceutical factory has been designated as a key wastewater discharge unit for 2024 in Chengdu, and has actively improved its environmental management level[172] - The company invested approximately 1.66 million yuan in environmental protection in 2024, covering clean production audits, online monitoring, and wastewater treatment operations[174] Shareholder Relations and Governance - The company held its first temporary shareholders' meeting in 2024 with a participation rate of 17.95% on January 31, 2024[123] - The company is committed to maintaining the legal rights of all shareholders through diligent board practices[143] - The board of directors approved a new compensation structure for executives, with an average increase of 15% in salaries[136] - The company has engaged in various investor relations activities to discuss business development and operational strategies throughout the reporting period[107] Strategic Commitments - The company has committed to avoiding any new competitive business activities with the listed company for a period of 5 years following the acquisition completion[182] - The company will take comprehensive measures, including asset injection and restructuring, to mitigate any potential adverse effects on the listed company due to overlapping business operations[182] - The company has pledged to avoid related party transactions with Taihe Health and its subsidiaries, ensuring fair and reasonable pricing[183]

Financial Performance - The company's revenue for Q1 2025 was CNY 126.91 million, a decrease of 29.21% compared to CNY 179.28 million in the same period last year[5]. - The net profit attributable to shareholders for Q1 2025 was a loss of CNY 14.59 million, representing a decline of 740.09% from a profit of CNY 2.28 million in Q1 2024[6]. - The company reported a basic and diluted earnings per share of CNY -0.0234, a decrease of 750.00% from CNY 0.0036 in the same period last year[5]. - Total operating revenue decreased to ¥126,911,245.23 from ¥179,277,340.12, representing a decline of approximately 29.2% year-over-year[21]. - Net profit for the period was ¥-14,501,128.77, compared to a profit of ¥4,123,269.28 in the previous period, indicating a significant loss[22]. - Basic and diluted earnings per share were both ¥-0.0234, down from ¥0.0036 in the previous period[23]. Cash Flow and Operating Activities - The net cash flow from operating activities improved by 64.52%, with a net outflow of CNY 8.88 million compared to CNY 25.04 million in the previous year[5]. - Cash received from operating activities decreased by 85.97% to CNY 2.03 million, largely due to the previous year's receipt of development funds[12]. - The net cash outflow from operating activities was -$8,881,767.85, an improvement from -$25,035,659.98 in the previous period, indicating a reduction in cash burn[25]. - Cash inflow from operating activities totaled ¥203,075,400.26, down from ¥228,953,557.57, a decrease of approximately 11.3% year-over-year[24]. Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 2.13 billion, down 5.26% from CNY 2.25 billion at the end of the previous year[5]. - The total assets decreased from 2,249,238,967.54 CNY to 2,130,996,832.61 CNY, a decline of approximately 5.3%[19]. - The total liabilities decreased from 1,200,000,000 CNY to 1,150,000,000 CNY, reflecting a reduction of about 4.2%[19]. - Total liabilities decreased to ¥1,077,403,955.40 from ¥1,181,257,849.14, a reduction of about 8.8%[20]. - Total equity attributable to shareholders decreased to ¥1,011,416,036.48 from ¥1,025,895,578.66, a decline of approximately 1.4%[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 42,293[14]. - Sichuan Huasheng Group holds 17.87% of shares, amounting to 111,431,281 shares, with 89,033,593 shares pledged[14]. - The number of shareholders with more than 5% ownership remains stable, with no significant changes reported in the top 10 shareholders[15]. Operating Costs and Income - The company's operating costs decreased by 32.98% to CNY 66.81 million, primarily due to reduced business volume in the steel structure segment[11]. - Other income fell by 50.49% to CNY 2.44 million, mainly due to a reduction in government subsidies during the reporting period[11]. - Total operating costs decreased to ¥143,848,298.92 from ¥177,333,754.20, a reduction of about 18.9% year-over-year[21]. Investment and Financing Activities - The company reported a significant increase of 199.21% in cash received from financing activities, amounting to CNY 118.07 million, primarily due to financing lease receipts[13]. - Cash inflow from financing activities totaled $154,116,045.35, compared to $177,459,549.62 in the prior period, reflecting a decrease in financing received[25]. - The company reported a net investment loss of ¥-309,393.86, compared to a loss of ¥-1,114,592.88 in the previous period, indicating an improvement in investment performance[22]. Other Financial Metrics - Research and development expenses increased to ¥3,675,818.30 from ¥3,325,261.93, an increase of about 10.5% year-over-year[22]. - Cash paid to employees amounted to $33,626,517.12, an increase from $31,835,743.16, indicating rising labor costs[25]. - Cash paid for taxes was $25,301,530.36, a slight decrease from $27,121,071.62, suggesting improved tax efficiency[25]. - The company did not undergo an audit for the first quarter report, which may affect investor confidence in the financial statements[27].